General Information of Drug (ID: DM826SW)

Drug Name
PF-04236921 Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM826SW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-6 (IL6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siltuximab DMGEATB Anemia 3A00-3A9Z Approved [4]
Sirukumab DMK8AQP Cutaneous lupus erythematosus EB5Z Phase 3 [1]
Olokizumab DM4Z9QI Rheumatoid arthritis FA20 Phase 3 [5]
Ziltivekimab DME841B Heart failure BD10-BD13 Phase 3 [6]
RG6179 DMO1VP9 uveitic macular edema 9B78 Phase 3 [7]
Clazakizumab DM6ZOUV Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [1]
CDP-6038 DM3YB2C Rheumatoid arthritis FA20 Phase 2 [8]
ALD-518 DMPWSBL Psoriatic arthritis FA21 Phase 2 [8]
YSIL6 DM0K8U7 Crohn disease DD70 Phase 2 [9]
Gerilimzumab DMA9UX2 Rheumatoid arthritis FA20 Phase 1 [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin (IL) TTF6I40 NOUNIPROTAC Inhibitor [3]
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01405196) Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus. U.S. National Institutes of Health.
3 US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
6 IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069.
7 Clinical pipeline report, company report or official report of Roche
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)